Artivion | CRY - Selling And Administration Expenses


Artivion reported $55.75M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Boston Scientific USD 1.8B 22M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 166.22M 12.01M Jun/2026
J&J USD 6.42B 381M Jun/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
ResMed USD 279.8M 1.4M Mar/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
Terumo JPY 114.81B 9.55B Mar/2026
Trinity Biotech USD 5.78M 405K Dec/2025